Alvotech's Vision for Growth with New Private Placement
Alvotech, traded on NASDAQ under the ticker ALVO, has announced its intention to pursue a private placement involving roughly 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares. This strategic initiative, aimed at both Swedish and international institutional investors, will utilize an accelerated bookbuilding procedure to facilitate the process. The placement is set to commence immediately, signaling the company’s proactive approach to expanding its investor base.
The Details of the Placement
Investors will be able to acquire shares via existing treasury shares held by Alvotech. The price and the total number of shares available will be determined through the accelerated bookbuilding conducted by DNB Carnegie and Citi, who are serving as Joint Global Coordinators and Bookrunners alongside SEB and ACRO. This stage is crucial as it establishes the market-driven pricing that aligns with investor demand and prevailing market conditions.
Timeline and Expectations
The completion and pricing for the placement are anticipated to align with the trading schedule on Nasdaq Stockholm, targeted before the opening bell on a specified date. However, the company retains the flexibility to adjust the timeline based on feedback from the bookbuilding process, reinforcing its responsiveness to market dynamics.
Strengthening the Shareholder Base
Alvotech's Board of Directors has recognized the importance of this private placement as a means to enrich its shareholder base with institutional investors, particularly following its recent listing of SDRs on Nasdaq Stockholm. Increasing the free float of these SDRs could leverage greater market participation and enhance shareholder engagement, ultimately contributing to a more robust capital structure.
Utilization of Proceeds
The net proceeds from this placement are earmarked for ambitious research and development activities, particularly in Sweden, which follow the acquisition of Xbrane's R&D operations. This funding will empower Alvotech to enhance its existing product pipeline, bolster growth opportunities in therapeutic areas, and maintain broad operational capacities.
Investment Insights for Potential Investors
Investors interested in participating in this placement have the option to acquire SDRs through Nasdaq Stockholm or ordinary shares available in Iceland (Icelandic Shares). The pricing structure aims to reflect current market conditions, reassuring investors of a fair valuation.
Commitment to Stability and Governance
Alvotech has pledged to uphold strict governance measures post-placement, with certain restrictions on issuing additional shares for a period following the settlement. This commitment extends to executive team members and board directors, ensuring a unified approach to governance that aligns with shareholders' interests.
The Advisors and Their Role
The facilitation of this placement is supported by notable financial institutions, with DNB Carnegie and Citi leading as Joint Global Coordinators. Their expertise will guide Alvotech through the complexities of the placement, supported by several legal advisory firms proficient in Swedish, Luxembourg, and Icelandic law. This ensures comprehensive oversight that meets regulatory and market expectations.
About Alvotech
With a foundational commitment to the development of biosimilar medications, Alvotech strives to be a prominent player in the pharmaceutical industry. Founded by Robert Wessman, Alvotech's mission extends to creating accessible, high-quality medicines that serve diverse patient populations globally. Currently, the company boasts an extensive pipeline, including products approved for markets worldwide, and continues to seek strategic partnerships that enhance its market reach and innovation potential.
Frequently Asked Questions
What is Alvotech's primary focus?
Alvotech is primarily focused on developing biosimilar medicines aimed at improving patient access to essential therapies globally.
What is the purpose of the upcoming private placement?
The private placement aims to expand the company's shareholder base and raise funds for R&D initiatives, particularly following a recent acquisition.
Who are the advisors involved in the placement?
DNB Carnegie and Citi act as Joint Global Coordinators, supported by SEB and ACRO as additional Joint Bookrunners.
What types of shares will be offered in the placement?
The placement will offer Swedish Depository Receipts (SDRs) and ordinary shares to investors.
How does Alvotech plan to use the proceeds from the placement?
Proceeds will be directed towards accelerating R&D efforts and expanding the product pipeline related to biosimilars.
